ipilimumab,nivolumab
bms
[]
-sustained separation of km curves, continued os benefit.
- higher orr across all evaluated pd-l1 cps subgroups #gi23 
Assistant Professor, GI Onc @OSUCCC_James @EinsteinMed Alum| @ClevelandClinic Alum| Interested in Drug Development|Precision Oncology|Cancer Disparities